Karuna Therapeutics (KRTX) Financials

$329.83

$0.00 (0.00%)

As on 18-Mar-2024 09:30EDT

Market cap

$12,599 Mln

Revenue (TTM)

$1 Mln

P/E Ratio

--

P/B Ratio

10

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Operating Revenue	0.65	10.64	36.96	--	--	--
Cost of Revenue	1.70	1.11	0.51	0.15	0.06	--
Gross Profit	-1.05	10.64	36.46	-0.15	-0.06	--
Operating Expenses	495.43	300.31	180.82	71.82	45.41	14.51
Operating Profit (EBIT)	-494.78	-289.68	-143.85	-71.82	-45.41	-14.51
Other Income	--	14.76	0.05	3.31	--	--
Profit before Tax	-433.01	-274.92	-143.80	-68.51	-43.96	-17.51
Provision for Tax	0.67	1.42	0.01	0.04	0.89	-0.42
Profit after Tax (Net Income)	-433.68	-276.34	-143.81	-68.55	-44.84	-17.51
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	-276.34	-143.81	-68.55	-43.96	-17.51

Liabilities ($ Mln)	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Shareholder's Funds	1,254.24	1,126.24	502.03	338.93	389.92	91.57
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	13.85	3.15	5.43	1.84	0.15	0.10
Current Liabilities	68.13	33.95	20.21	6.85	2.96	0.81
Total Liabilities	1,336.21	1,163.33	527.67	347.63	393.02	92.48

Assets ($ Mln)	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Non-Current Assets	20.90	8.57	10.34	3.03	0.32	0.26
Current Assets	1,315.31	1,154.77	517.33	344.60	392.71	92.22
Total Assets	1,336.21	1,163.33	527.67	347.63	393.02	92.48
Total Debt*	16.69	5.33	7.50	2.69	0.21	0.10
Net Current Assets	1,247.18	1,120.82	497.12	337.75	389.75	91.41

Cashflow ($ Mln)	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Cash From Operating Activities	-385.82	-228.01	-100.88	-69.86	-30.92	-15.38
Cash Flow from Investing Activities	--	-586.40	-22.69	-89.65	-174.34	-5.12
Cash from Financing Activities	483.37	855.78	277.58	3.66	405.28	27.58
Net Cash Inflow / Outflow	--	41.38	154.01	-155.85	--	--

Financials Ratios	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Adjusted EPS ($)	-11.72	-8.64	-4.96	-2.64	-3.74	--
Cash EPS ($)	-11.68	-8.60	-4.94	-2.63	-3.73	--
Adjusted Book Value ($)	33.90	35.19	17.31	13.04	32.49	--
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	-10.43	-7.13	-3.48	-2.69	-2.58	--
Free Cash Flow per Share ($)	-10.51	-7.15	-3.58	-2.70	-2.59	--

Profitability Ratios	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
ROCE (%)	-36.10	-33.68	-33.79	-18.74	-18.62	-38.93
ROE (%)	-36.44	-33.94	-34.20	-18.81	-18.63	-44.79
ROA (%)	-34.70	-32.68	-32.86	-18.51	-18.47	-37.02
EBIT Margin (%)	-75,653.98	-2,723.29	-389.17	--	--	--
Net Margin (%)	-66,311.93	-1,088.15	-388.47	-2,074.25	--	--
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Revenue Growth (%)	-0.94	-0.71	--	--	--	--
EBIT Growth (%)	-70.80	-101.37	-100.31	-58.17	-213.46	-201.39
Net Profit Growth (%)	-56.94	-92.16	-109.77	-52.87	-156.08	-190.32
EPS Growth (%)	-0.36	-0.74	-0.88	0.29	--	--
Book Value Growth (%)	--	--	--	--	--	--

Valuation Ratios	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Price / Earnings	-27.00	-22.75	-26.42	-38.53	-20.16	--
Price / Book Value	9.34	5.58	7.57	7.79	2.32	--
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-21.22	-17.91	-23.14	-33.89	-12.01	--
Close Price ($)	316.51	196.50	131.00	101.59	75.34	--
High Price ($)	318.75	278.25	161.98	123.73	152.00	--
Low Price ($)	158.38	92.26	94.84	52.62	11.24	--
Market Cap ($ Cr)	--	--	--	--	--	--

Solvency Ratios	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Debt to Equity	0.01	0.00	0.01	0.01	0.00	0.00
Short term debt to equity ratio	0.00	0.00	0.00	0.00	0.00	--
Current Ratio	19.31	34.02	25.59	50.28	132.76	114.27
Quick Ratio	18.82	33.18	24.56	--	--	--
Interest Coverage	--	-20.43	-1,013.05	-495.28	-48.05	-5.61

Operating Efficiency Ratios	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Debtors to sales (%)	749.24	0.54	4.73	--	--	--
Asset Turnover	0.00	0.01	0.08	--	--	--
Receivable days	1,384.21	31.02	8.65	--	--	--
Inventory Days	6,565.91	8,081.81	15,075.59	--	--	--
Payable days	983.66	709.15	1,012.02	1,778.39	2,569.34	--
Cash Conversion Cycle	6,966.46	7,403.69	14,072.21	--	--	--